Br J Ophthalmol 89:648-649 doi:10.1136/bjo.2005.065854
  • Editorial

Is ex vivo adenovirus mediated gene transfer a therapeutic option for the treatment of corneal diseases?

  1. T Ritter1,
  2. N Gong2,
  3. U Pleyer2
  1. 1Institute of Medical Immunology, Charité–University Medicine Berlin, Germany, and Regenerative Medicine Institute, National University of Ireland, Galway, Ireland
  2. 2Department of Ophthalmology, Charité–University Medicine Berlin, Germany
  1. Correspondence to: Thomas Ritter PhD, Institute of Medical Immunology, Charité–University Medicine Berlin, Campus Mitte, Monbijoustrasse 2a, 10117 Berlin, Germany;

    Improvements in vectors, promoters, and transgenes have to be accomplished before gene therapy could be considered as an option in cornea gene therapy

    Currently there are almost 1000 clinical trials for the treatment of cancer, inherited monogenic diseases, and cardiovascular diseases.1 Viral vectors have been used extensively to transduce human cells or tissues, mostly retroviruses and adenoviruses representing the majority because of their transduction efficiency compared to other gene transfer techniques (liposomes, gene gun, electroporation). However, further progress in gene medicine has been compromised by severe problems that arose in clinical trials using recombinant adenoviruses or retroviruses. Severe side effects resulted either from “overdosing” of adenoviral particles resulting in fulminant inflammation or from retroviral insertion into the genomic DNA leading to deregulated proliferation of transduced cells.

    The question arises whether there could be a therapeutic option for gene therapy in the treatment of non-life threatening diseases? If there is a consensus that this could be useful, there are some important prerequisites: the gene therapeutic vehicle has to be safe, it should be specifically expressed only in the target cells/tissues without …